Tag: Paroxysmal supraventricular tachycardia
First patient randomised in the phase 3 NODE-301 trial evaluating etripamil
Milestone Pharmaceuticals, a clinical-stage cardiovascular company, announced that the first patient has been randomised in its phase 3 clinical study of etripamil. Etripamil is...
HRS 2017: Could etripamil nasal spray be a “game-changer” for paroxysmal...
A phase 2 trial (NODE-1) of a nasal spray formulation of etripamil (Milestone Pharmaceuticals) shows it is safe and effective at terminating paroxysmal supraventricular...